Does Bempedoic Acid And Ezetimibe Interact with Cholestyramine Light?
CDI records a moderate classification for Bempedoic Acid And Ezetimibe and Cholestyramine Light. The stored summary is: Concomitant use decreases ezetimibe concentration, potentially reducing efficacy. Administer NEXLIZET at least 2 hours before or 4 hours after cholestyramine. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Bempedoic Acid And Ezetimibe Class
- Adenosine Triphosphate-Citrate Lyase Inhibitor
- Cholestyramine Light Class
- Bile Acid Sequestrant
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
What To Tell Your Doctor or Pharmacist
If you are taking Bempedoic Acid And Ezetimibe and your doctor is considering prescribing Cholestyramine Light (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider